Health
Gilead Shot Prevents All HIV Cases in Trial of African Women
- First big trial to reduce HIV infections to zero, Gilead says
- Shares of drugmaker jump the most in over a year and a half
Gilead Sciences headquarters in Foster City, California.
Photographer: David Paul Morris/BloombergThis article is for subscribers only.
Gilead Sciences Inc.’s experimental twice-yearly shot prevented 100% of HIV cases in women and adolescent girls in Africa, the first successful big trial of what’s hoped to become a powerful new drug regimen for fending off the virus.
Gilead hopes its new long-acting shot lenacapavir will provide an easier-to-use option compared to other HIV prevention drugs that are either daily pills or must be injected every two months. The two yearly injections could be done at regularly scheduled doctor visits, making it easy for people to get.